Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I figured. Thanks, Phyto.
You can probably figure out what the CTO document is by the context. Someone just has to go figure out from the 10-k what Exhibit 10.57 relates to. Most likely it is money terms related to the Amgen deal, if I had to guess. Milestones, royalty percentages, etc. Or, it could be the identity of the private placement purchaser in August.
The CTO must be something good. CTOs are not used for negative information. Their purpose is to protect a company's trade secrets. You cannot hide bad developments with a CTO.
Lol. They are taking their bacteria and going home.
Agreed. Would actually require an 8-k.
Aren't there possible reasons for ADRO suspending a trial aside from an FDA hold? By the way, I notice that the FDA website doesn't include patients with implants under the exclusion criteria. I wonder if that is the reason for the suspension.
Easy, by any chance do you drink a lot of coffee? lol
You're right, FBG. I had a brain fart on that one. Lower 5% threshold is merely for Rule 13.
Niiiice. Blackrock upping their stake. Now an insider.
Traders look for any excuse to act in concert without expressly agreeing to it. So when they see an imminent bad sector day they all hop on board, and short the individual stocks. Actually, I think ADXS may be part of the XBI, but not the IBB.
The sector action is often stronger than individual news. Sector taking a hit today. That's all it is.
What is the date of the presentation?
There is a lot of leeway in the terms "adequate safety and effectiveness." Agency's are generally given fairly broad discretion, i.e. Rulemaking authority. Congress generally sets a rough framework with general terms and then defers to the agency's superior expertise on how to implement it.
Well, you don't really know for sure when covering is occurring. It is largely interpretative. But "real" trading in this stock is very light (as opposed to the robots trading 56 shares back and forth to each other all day), so when there is any significant real buying (or selling) it sticks out pretty clearly in the price/volume action, as he noted.
Bill, not necessarily today, but in general I agree. Short covering.
Yes, something needs to change. What needs to change is the shorts, who are living on borrowed time and borrowed shares. They cannot manipulate and suppress forever. They will either decide to stop on their own or be forced to stop by significant accumulation, which is not something their robots can manipulate against. However, none of this has anything to do with Dan or the state of the company. Except that, obviously, big news will likely be the cause of the "real" pps reversal.
That is a possibility, Bourbon. However, if that does happen then something went wrong substantively to justify the low valuation. No evidence of that occurring.
In what way has he underperformed, substantively? I thought everyone was happy with the clinical trial progress, possible early EU, and the Amgen deal, etc. What other "performance" is within his direct control? Answer: nothing.
I hear you, Bourbon, but the reality is that they probably would have taken it down exactly to where they actually did take it down, regardless of the private placement at 13.50.
Deck, you referring to the Gerritsen article Petit posted? Seems to me that he simply posted it as a matter of general interest.
When is the next update on prostate expected?
Sorry, Deck, I haven't seen it. I don't have any clue how to use Twitter. lol
Very "few," I meant.
Interestingly, there are very open options positions for February through July. I recall the open contracts being alot higher than that--on both sides--last I checked a couple of months ago. Many must have been closed out.
It'll happen when you least expect it. That's how it works.
Not exactly. Pps ran from 7.75 to 10.25 back in November. And another rise in late December in late December into January. Those periods are when the covering occurred. Then, once the volume dries up after the periods of covering the HFT manipulators work it back down on the light, largely-fake volume.
What? You are thinking merger or acquisition between ADXS and ADRO?
What's up with that? No news on the wire. Either a leak, or just someone screwing around.
Because, FBG, I believe management has an impact on value, not share price. The share price and the value are disconnected. Not to mention that the science is the most important "value" issue, not management. This is a company whose value is in its unmonetized science, and not much else. All you can ask of management, when dealing with a very promising developing technology, is that they manage the development programs effectively, forge key relationships with BP's, and keep the company funded until judgment day. Management has done all of that just fine thus far. And the value far exceeds the share price.
Illogical. The tutes know the time frame for ADXS better than we do, you can bet on that. And they also know that we are much further along in the time frame now then when they first got in. They will not be selling in the future, they will be buying. They are not retail. They don't hold through the dog days, then lose patience and sell low, only to watch the good stuff happen. They are a little more sophisticated than that. In other words, your soft bashing would never work on them.
Option 3, the manipulators stop manipulating and tutes start buying into young biotechs again, making the pps improve regardless of what Dan has done or not done. Which is all that it has ever been anyway.
DOC apparently convinced Adage, Broadfin, Fidelity, etc. Not that your premise that the CEO convincing investors is valid. It's nonsense. Particularly for a biotech, where trial results and pre-clinical testing results are all that big investors need in order to evaluate a company.
They would have taken the stock down at some point after the Amgen deal regardless of the private placement.
Bourbon, the decline was caused by traders and mm's taking advantage of: (1) a dearth of real volume, due to hedgies and funds being defensive, particularly as to biotech; (2) a very weak biotech market, scared of Hillary (and now Trump)--see No, 1; and (3) HFT manipulation, churning, laddering down, etc.
That is exactly my view. Since there is no justifiable reason whatsoever for the current low share price, there is nothing "bad" that needs to be attributed to anyone in the first place. Raising working capital is not a mistake, and neither is it a reason to severely adjust a company's valuation. It comes as a surprise to analysts and the street? This is a clinical biotech with a dozen irons in the fire, for cripes sake.
Since when have shorts ever needed a reason to work the stock down? The more progress the company made, the more they manipulated and shorted, for the last 18 months.
Exactly. The private placement did not cause or justify the significant decline below the placement price.
Easy, I think you are ignoring the speed with which EU approval is possible. Can't wait til the last minute for a distribution plan.
Seems pretty clear that the traders/mm's the last few weeks are anticipating (or worried about) Wednesday news. Then they work it back down when it doesn't come.
Interesting that ADXS would highlight that article, which is relevant to ADXS but also relatively tenuous. Trying to figure out if it signals anything other than providing general information.